| Document And Entity Information - shares | 3 Months Ended | |
| Mar. 31, 2022 | Apr. 29, 2022 |
| Document Information Line Items | | |
| Entity Registrant Name | OptimizeRx
Corporation | |
| Trading Symbol | OPRX | |
| Document Type | 10-Q/A | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Common Stock, Shares Outstanding | | 18,152,349 |
| Amendment Flag | true | |
| Amendment Description | OptimizeRx
Corporation is filing this Amendment No. 1 on Form 10-Q/A (“Amendment No. 1”) to its Quarterly Report on Form 10-Q for the
period ended March 31, 2022, originally filed with the Securities and Exchange Commission (SEC) on May 9, 2022 (the “Original
10-Q Filing”) to address management’s re-evaluation of disclosure controls and procedures and to reflect the identification
of a material weakness. The material weakness did not result in any change to the Company’s consolidated financial statements as
set forth in the Original 10-Q Filing.This
Amendment No. 1 is limited in scope to make the following changes to the Original 10-Q Filing:
●To
amend Part I - Item 4. Controls and Procedures to reflect management’s (i) re-evaluation
of our disclosure controls and procedures, and (ii) identification of a material weakness.
●To
amend Part II - Item 6. Exhibits to include the following currently dated documents: certifications
from the Company’s Chief Executive Officer and Chief Financial Officer as required
by Sections 302 and 906 of the Sarbanes Oxley Act of 2002, which certifications are filed
herewith as Exhibits 31.1, 31.2, and 32.1.This
Amendment No. 1 has not been updated or amended to give effect to any subsequent events beyond those that existed as of the original
filing date and should thus be read in conjunction with the Original 10-Q Filing and any of the company’s other filings with the
SEC subsequent to the Original 10-Q Filing, together with any amendments to those filings. Other than the filing of the information identified
above, this amendment does not modify or update the disclosure in the Original 10-Q Filing in any way. Unless
otherwise specified or the context otherwise requires, when used in this Amendment No. 1, the terms “we,” “our,”
“us,” “OptimizeRx,” or the “Company” refer to OptimizeRx Corporation and its subsidiaries.The
Company is concurrently filing Amendment No. 1 to each of its (i) Annual Report on Form 10-K for the year ended December 31, 2021 and
(ii) Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2022 and September 30, 2022. | |
| Entity Central Index Key | 0001448431 | |
| Entity Current Reporting Status | Yes | |
| Entity Filer Category | Large Accelerated Filer | |
| Document Period End Date | Mar. 31, 2022 | |
| Document Fiscal Year Focus | 2022 | |
| Document Fiscal Period Focus | Q1 | |
| Entity Small Business | false | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Entity File Number | 001-38543 | |
| Entity Incorporation, State or Country Code | NV | |
| Entity Tax Identification Number | 26-1265381 | |
| Entity Address, Address Line One | 400
Water Street | |
| Entity Address, Address Line Two | Suite 200 | |
| Entity Address, City or Town | Rochester | |
| Entity Address, State or Province | MI | |
| Entity Address, Postal Zip Code | 48307 | |
| Local Phone Number | 651-6568 | |
| City Area Code | 248 | |
| Title of 12(b) Security | Common Stock, par value $0.001 | |
| Security Exchange Name | NASDAQ | |
| Entity Interactive Data Current | Yes | |
